Towards a universal second-line fixed-dose combination ART
Lancet HIV
.
2018 Jan;5(1):e3-e5.
doi: 10.1016/S2352-3018(17)30180-7.
Epub 2017 Oct 6.
Authors
Mark A Boyd
1
,
David A Cooper
2
,
Charles F Gilks
3
Affiliations
1
University of Adelaide, Lyell McEwin Hospital, Adelaide, SA 5112, Australia. Electronic address: mark.boyd@adelaide.edu.au.
2
Kirby Institute, University of New South Wales Australia, NSW, Australia.
3
School of Public health, University of Queensland, Queensland, Australia.
PMID:
28993181
DOI:
10.1016/S2352-3018(17)30180-7
No abstract available
Publication types
Comment
MeSH terms
Anti-HIV Agents*
HIV Infections*
Humans
Nevirapine
Substances
Anti-HIV Agents
Nevirapine